Canine Sarcoidosis Treated Successfully With Oclacitinib: A Case Report.

Oclacitinib achieved remission in a dog with cutaneous sarcoidosis refractory to conventional diagnostics.

This case report documents the successful treatment of canine cutaneous sarcoidosis in a male Finnish Lapphund presenting with widespread papular skin lesions. Diagnosis was confirmed through histopathological examination, with extensive diagnostic workup including bacterial and fungal cultures, special staining techniques, electron microscopy, and in situ hybridization performed to rule out infectious etiologies. Despite these comprehensive investigations, no specific causative agent was identified, supporting a diagnosis of idiopathic sarcoidosis. The condition was successfully managed with oral oclacitinib, a selective JAK1 inhibitor commonly used in canine dermatology for pruritic conditions. This case represents an important addition to the limited literature on canine sarcoidosis treatment and demonstrates the potential therapeutic utility of oclacitinib for non-pruritic inflammatory skin conditions. The achievement of remission suggests that JAK inhibition may be an effective immunomodulatory strategy for managing cutaneous sarcoidosis in dogs, offering an alternative to traditional systemic corticosteroid therapy.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.